A panel of research-based drug industry leaders recently convened by the Tufts Center for the Study of Drug Development (CSDD) reported that drug companies are engaging in innovative partnerships that are leading to more molecular entities entering Phase I trials and shorter study times. “Drug developers have gotten the message that they need to innovate ‘better, faster, and cheaper’ — without sacrificing patient safety — and partnering is proving to be an effective strategy,&...